Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-07-25
DOI
https://doi.org/10.3389/fphar.2025.1580883
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial

Cuiyun Li, Qingfeng Dong, Jia Xu, Zhi‐Jie Liu et al.
Frontiers in Pharmacology
Monoclonal and Polyclonal Antibodies Research
article

Comparison of pharmacokinetic similarity, immunogenicity, and safety of mepolizumab and BAT2606 in healthy Chinese men in a double-blinded, randomized, single-dose, three-arm parallel-group phase I trial

Cuiyun Li, Qingfeng Dong, Jia Xu, Zhi‐Jie Liu, Jixuan Sun, Yu Sun, Xiaojiao Li, Yanhua Ding, Min Wu
article en

Abstract

No abstract available for this paper.
Frontiers in PharmacologyVol. 16
Jilin University (CN), First Hospital of Jilin University (CN)
Good health and well-being
Openalex Percentile: Top 72%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.